JAK Inhibitors Outperform TNF Blockers in Rheumatoid Arthritis Treatment
New Study Finds Baricitinib Superior in Reducing RA Symptoms Compared to TNF Inhibitors
Topline: A new study demonstrates that baricitinib, a Janus kinase (JAK) inhibitor, significantly reduces rheumatoid arthritis (RA) symptoms more effectively than tumor necrosis factor (TNF) blockers. Thus, it offers a promising alternative for patients who do not respond to conventional anti-rheumatic drugs.
Study Details: Rheumatoid arthritis (RA) pati…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.